CHLA Clinical Research Studies

Having volunteers participate in research studies and clinical trials is critical to our research efforts. Thousands of children and families are involved in our patient-centered studies every year. Many of the treatments used today are based on the results of past research studies and clinical trials conducted with our patients. Our scientific and clinical experts take the best ideas from the laboratory -- to the patient -- in the form of promising new treatments.

By searching our study directory, you may identify research that could impact the life of your child or of another child you know. Because the number of available research studies and clinical trials for children nationwide is small, every participant makes a significant contribution.

In addition to enrolling children with certain diseases in order to study treatments and prevention of those diseases, we also need to study healthy children. Ask your child’s doctor about volunteer study options that may be suitable for your child.

Please contact the study staff listed in your search results for more information.

Search by Keyword:    

Back to the full listing

Study Details - ID: CHLA-18-00451
Health/Science/Disease Category:
Type 1 Diabetes (T1D)
Purpose of Research:
Hydroxychloroquine is given as an investigational drug to relatives of someone with type 1 diabetes who have positive diabetes antibodies in an attempt to prevent or delay the onset of type 1 diabetes. See website for more details
Short Name:
HCQ Prevention (TN22)
Full Title of Study:
Hydroxychloroquine for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-Risk for Type 1 Diabetes Mellitus
Phase/Type of Study:
Phase 2
1. Be identified as having 2 or more positive autoantibodies in the TrialNet Pathway to Prevention Study (TN01). 2. Be aged 3 or older and weigh more than 12 kg. 3. Have normal glucose tolerance by oral glucose tolerance test within 7 weeks of the baseline study visit.
Time Commitment/Requirements:
The treatment includes a daily oral tablet(s). The study involves 5 visits in the first 6 months, then 1 visit every 6 months for the remainder of the study. Compensation provided for all visits.
Primary Investigator:
Roshanak Monzavi, MD
Coordinator Contact Name:
Debra Miller, BSN, CDE
Phone Number:
Clinical Trials .Gov Identifier: